Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer immunotherapies, their safety and toxicity
Gheath Alatrash, Haroon Jakher, Patricia Stafford, et al.
Expert Opinion on Drug Safety (2013) Vol. 12, Iss. 5, pp. 631-645
Closed Access | Times Cited: 137

Showing 1-25 of 137 citing articles:

Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu, David J. Waxman
Cancer Letters (2018) Vol. 419, pp. 210-221
Open Access | Times Cited: 291
Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates
Manpreet Sambi, Leila Bagheri, Myron R. Szewczuk
Journal of Oncology (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 270
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
Ventola Cl
PubMed (2017) Vol. 42, Iss. 8, pp. 514-521
Closed Access | Times Cited: 237
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Filippo Galli, Jesus Vera Aguilera, Belinda Palermo, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 230
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Arsen Osipov, May Tun Saung, Lei Zheng, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 195
Advancing to the era of cancer immunotherapy
Yun Wang, Min Wang, Hao‐Xiang Wu, et al.
Cancer Communications (2021) Vol. 41, Iss. 9, pp. 803-829
Open Access | Times Cited: 131
Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies
Pratiksha Tiwari, Ravi Prakash Shukla, Krishna Yadav, et al.
Journal of Molecular Graphics and Modelling (2024) Vol. 128, pp. 108702-108702
Closed Access | Times Cited: 19
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Yangyang Xu, Bing Wan, Xi Chen, et al.
Translational Lung Cancer Research (2019) Vol. 8, Iss. 4, pp. 413-428
Open Access | Times Cited: 142
Dendritic cell therapy in cancer treatment; the state-of-the-art
Mahsa Sadeghzadeh, Soghra Bornehdeli, Haniye Mohahammadrezakhani, et al.
Life Sciences (2020) Vol. 254, pp. 117580-117580
Closed Access | Times Cited: 132
Long noncoding RNAs in cancer‐immunity cycle
Weidi Yu, Huanhuan Wang, Qifeng He, et al.
Journal of Cellular Physiology (2018) Vol. 233, Iss. 9, pp. 6518-6523
Closed Access | Times Cited: 124
The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy
Zihao Xu, Peiyao Li, Li Fan, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 121
Cancer Immunotherapy, Part 1: Current Strategies and Agents.
Ventola Cl
PubMed (2017) Vol. 42, Iss. 6, pp. 375-383
Closed Access | Times Cited: 108
Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
Laurel B. Darragh, Ayman Oweida, Sana D. Karam
Frontiers in Immunology (2019) Vol. 9
Open Access | Times Cited: 106
Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers
Sourabh Shukla, Jay Myers, Sarah E. Woods, et al.
Biomaterials (2016) Vol. 121, pp. 15-27
Closed Access | Times Cited: 98
Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.
C Lee Ventola
PubMed (2017) Vol. 42, Iss. 7, pp. 452-463
Closed Access | Times Cited: 88
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate
Rosemina Merchant, Carole L. Galligan, Manjunatha Ankathatti Munegowda, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003155-e003155
Open Access | Times Cited: 41
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Subhamay Adhikary, Surajit Pathak, Vignesh Palani, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 217-217
Open Access | Times Cited: 10
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Arsen Osipov, Adrian Murphy, Lei Zheng
Advances in cancer research (2019), pp. 63-144
Closed Access | Times Cited: 60
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
Pu Sun, Linghua Meng
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 11, pp. 1395-1402
Open Access | Times Cited: 52
Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation
Pier Edoardo Rovatti, Valentina Gambacorta, Francesca Lorentino, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 51
Curcumin as an Adjuvant to Cancer Immunotherapy
Silpita Paul, Gaurisankar Sa
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 48
Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
Chiara Cremolini, Emanuela Vitale, Raffaella Rastaldo, et al.
Nanomaterials (2021) Vol. 11, Iss. 3, pp. 661-661
Open Access | Times Cited: 44
T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review
Jessica Wu, Sudiksha Dand, Lachlan Doig, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 44
Natural products targeting inflammation-related metabolic disorders: A comprehensive review
Firzan Nainu, Andri Frediansyah, Sukamto S. Mamada, et al.
Heliyon (2023) Vol. 9, Iss. 6, pp. e16919-e16919
Open Access | Times Cited: 21
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
Edoardo G. Giannini, Andrea Aglitti, Mauro Borzio, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1689-1689
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top